Cocrystal Pharma gains on influenza drug trial data

Cocrystal Pharma

17/11/2022 14:24

** Shares of Cocrystal Pharma Inc  COCP.O  up 7% at $3.21
premarket
    ** Co says its experimental antiviral drug, CC-42344, for
treating pandemic and seasonal influenza caused by influenza
type A virus, shows favorable safety profile in early-stage
study 
    ** Clean safety profile observed with all dose levels in two
portions of the study - COCP 
    ** Co to assess trial data about how the drug interacts with
 body in the coming weeks 
    ** On track to report topline results of the trial later
this year - COCP 
    ** As of last close, stock was down 61.5% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))